LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

NCT00805194 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1314

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: placebo plus docetaxel
DRUG: BIBF 1120 plus docetaxel

Sponsor

Boehringer Ingelheim